We are live on
!
Find out more
Federated Hermes Portfolio holdings
AUM
$69.6B
1-Year Est. Return
42.52%
This Fund
S&P 500
This Quarter
Est. Return
+5%
1 Year Est. Return
+42.52%
3 Year Est. Return
+132.48%
5 Year Est. Return
+152.58%
10 Year Est. Return
+652.43%
AUM
$40.3B
AUM Growth
+$535M
(+1.3%)
Cap. Flow
-$468M
Cap. Flow
% of AUM
-1.16%
Top 10 Holdings %
Top 10 Hldgs %
15.78%
Holding
2,279
New
170
Increased
711
Reduced
1,071
Closed
189
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Amgen
AMGN
|
+$178M |
| 2 |
LyondellBasell Industries
LYB
|
+$133M |
| 3 |
AT&T
T
|
+$124M |
| 4 |
Stanley Black & Decker
SWK
|
+$101M |
| 5 |
Pfizer
PFE
|
+$93.4M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Clorox
CLX
|
+$229M |
| 2 |
Gilead Sciences
GILD
|
+$164M |
| 3 |
Broadcom
AVGO
|
+$149M |
| 4 |
KeyCorp
KEY
|
+$145M |
| 5 |
Darden Restaurants
DRI
|
+$125M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 20.22% |
| 2 | Technology | 14.47% |
| 3 | Financials | 10.84% |
| 4 | Industrials | 9.01% |
| 5 | Consumer Discretionary | 8.84% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
651
Infosys
INFY
$45.8B
| $6.11M | 0.02% |
379,989
+96,450
| +34% | +$1.51M |
|
|
ETRN
652
DELISTED
Equitrans Midstream Corporation Common Stock
ETRN
| $6.08M | 0.02% |
636,383
+568,191
| +833% | +$3.81M |
|
653
DoorDash
DASH
$85.9B
| $6.08M | 0.02% |
79,503
+79,459
| +180,589% | +$5.27M |
|
654
Federated Hermes US Strategic Dividend ETF
FDV
$900M
| $6.06M | 0.02% |
255,000
+165,000
| +183% | +$3.94M |
|
655
Goldman Sachs
GS
$284B
| $6.05M | 0.02% |
18,763
+1,305
| +7% | +$429K |
|
656
SunCoke Energy
SXC
$803M
| $6.05M | 0.02% |
768,254
+92,555
| +14% | +$727K |
|
657
Aspen Aerogels
ASPN
$403M
| $5.92M | 0.01% |
750,000
| – | – |
|
658
Byline Bancorp
BY
$1.73B
| $5.92M | 0.01% |
327,103
-149,406
| -31% | -$2.81M |
|
659
GE Aerospace
GE
$319B
| $5.84M | 0.01% |
66,566
+7,241
| +12% | +$586K |
|
660
The Joint Corp
JYNT
$120M
| $5.8M | 0.01% |
429,624
-31,772
| -7% | -$466K |
|
661
ACV Auctions
ACVA
$1.77B
| $5.78M | 0.01% |
+334,891
| New | +$5.12M |
|
662
Molson Coors Class B
TAP
$7.32B
| $5.77M | 0.01% |
87,683
-89,656
| -51% | -$5.54M |
|
663
Watts Water Technologies
WTS
$11.7B
| $5.73M | 0.01% |
31,161
-683
| -2% | -$114K |
|
664
Howmet Aerospace
HWM
$89.6B
| $5.7M | 0.01% |
115,099
-122
| -0.1% | -$5.43K |
|
|
RGLS
665
DELISTED
Regulus Therapeutics
RGLS
| $5.7M | 0.01% |
3,875,578
+970,752
| +33% | +$1.29M |
|
666
MasterBrand
MBC
$1.42B
| $5.65M | 0.01% |
485,709
-1,865
| -0.4% | -$17.9K |
|
|
ALE
667
DELISTED
Allete
ALE
| $5.65M | 0.01% |
97,424
+36,013
| +59% | +$2.23M |
|
668
MiMedx Group
MDXG
$689M
| $5.59M | 0.01% |
846,250
-106,958
| -11% | -$545K |
|
669
Visteon
VC
$2.61B
| $5.58M | 0.01% |
38,869
+20,563
| +112% | +$2.93M |
|
|
EFOR
670
Everforth Inc
EFOR
$1.39B
| $5.48M | 0.01% |
72,479
-3,344
| -4% | -$240K |
|
671
Mistras Group
MG
$626M
| $5.48M | 0.01% |
709,445
-10,229
| -1% | -$76.1K |
|
|
FITB
672
Fifth Third Bancorp
FITB
$49.6B
| $5.47M | 0.01% |
208,565
+4,816
| +2% | +$124K |
|
673
Arlo Technologies
ARLO
$1.45B
| $5.43M | 0.01% |
+497,823
| New | +$4.05M |
|
674
Hyster-Yale Materials Handling
HY
$599M
| $5.38M | 0.01% |
96,279
+96,045
| +41,045% | +$4.91M |
|
|
MRSH
675
Marsh
MRSH
$85.8B
| $5.36M | 0.01% |
28,481
+369
| +1% | +$65.5K |
|
Similar funds
Federated Hermes's Q2 2023 Portfolio in Review
As of Q2 2023, Federated Hermes held 2,279 positions worth $40.3B, up 1.3% from $39.7B the previous quarter. Its ten largest holdings account for 16% of the portfolio.
Federated Hermes's Q2 2023 filing shows 170 new, 711 increased, 1,071 reduced and 189 closed positions. Its largest new stake was HashiCorp, Inc. Class A Common Stock: 1,317,400 shares worth $34.5M. The largest sale was Clorox, an estimated $229M.
By sector, the portfolio is most concentrated in Healthcare at 20% of assets, up from 20% a quarter earlier, followed by Technology and Financials.
- Federated Hermes's largest Q2 2023 buy was HashiCorp, Inc. Class A Common Stock: 1,317,400 shares worth $34.5M.
- Federated Hermes added most to Amgen in Q2 2023, an estimated $178M increase.
- Federated Hermes's biggest Q2 2023 reduction was Clorox, cutting an estimated $229M.
- Federated Hermes fully exited Prometheus Biosciences, Inc. Common Stock in Q2 2023, selling an estimated $55.4M.
- Federated Hermes's ten largest holdings make up 16% of its $40.3B portfolio in Q2 2023.
- Federated Hermes opened 170 new positions and closed 189 in Q2 2023.
- Federated Hermes's portfolio value rose 1.3% quarter-over-quarter to $40.3B.
Based on Federated Hermes's 13F filing for Q2 2023, filed 14 Aug 2023.